By Lorraine Nelson, WSU Spokane
SPOKANE, Wash. – A genetic testing company will make available tests for prostate cancer survival and breast cancer recurrence to patients following identification of the biomarker genes in a Washington State University laboratory.
Ultimately, the goal is to validate the accuracy of the genetic tests and create the best treatment plans for patients based on their individual expression of the genes.
Identification of the biomarkers is another in a series of scientific advancements made in the laboratory of Grant Trobridge, a microbiologist in the Department of Pharmaceutical Sciences at WSU. Prior to coming to WSU, he was a staff scientist at the Fred Hutchinson Cancer Research Center in Seattle and a research assistant professor in the University of Washington’s Department of Medicine.
“Genes express differently in each individual, and so each person has a different genetic profile or signature,” Trobridge said. “The clinical data will be analyzed for patterns to see what treatment best fits each of the profiles.”
Validation studies, treatment plans
Trobridge worked with the WSU Office of Commercialization to establish the partnership and negotiate licensing agreements with Datar Genetics Ltd. in India. Datar was among companies in Europe, Asia, Canada and the U.S. identified as potential partners.
As part of the agreement, Datar will continue to conduct validation studies to assess the efficacy of the test. Datar will work alongside patients and clinicians in India to determine how to use the technology in developing individualized treatment plans.
License agreements with additional companies are expected once the validation studies are complete.
Viruses transfer genetic materials
Trobridge’s lab identified 16 genes as biomarkers for predicting prostate cancer survival and four genes as biomarkers for predicting breast cancer recurrence after treatment. The work was supported by a grant from the National Cancer Institute and follows years of progressive development by the lab of viruses that successfully transfer genetic materials to genes and red blood cells.
The prostate cancer work began about two years ago after the lab developed a technique that showed promise for identifying genes involved in the cancer’s progression. The researchers used a virus to cause mutations in the genes to find out which mutations resulted in the progression of cancer. That work was led by Arun Nalla, a postdoctoral research associate.
The breast cancer work used a virus that normally causes leukemia but has the ability to insert its DNA into the genome of a human cell. This allowed the researcher to “tag” those genes believed to be involved in breast cancer metastasis and follow them to learn how they were involved. That work was led by Victor Bii, a Ph.D. student studying with Trobridge for several years.